In a report released on November 22, Luca Issi from RBC Capital maintained a Buy rating on uniQure (QURE – Research Report), with a price target of $53.00. The company’s shares closed yesterday at $26.90.
Issi covers the Healthcare sector, focusing on stocks such as Alnylam Pharma, uniQure, and Arrowhead Pharmaceuticals. According to TipRanks, Issi has an average return of -15.9% and a 31.52% success rate on recommended stocks.
Currently, the analyst consensus on uniQure is a Strong Buy with an average price target of $56.29, implying a 109.26% upside from current levels. In a report released on November 23, Goldman Sachs also maintained a Buy rating on the stock with a $57.00 price target.
See the top stocks recommended by analysts >>
Based on uniQure’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $1.45 million and a GAAP net loss of $47.86 million. In comparison, last year the company earned a revenue of $1.99 million and had a GAAP net loss of $36.53 million
Based on the recent corporate insider activity of 47 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of QURE in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
uniQure NV engages in the research, development, and commercialization of gene therapies. Its discoveries intend to treat hemophilia, Huntington’s disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, the Netherlands.
Read More on QURE:
- QURE: The Most Expensive Treatment EVER Is Here
- uniQure announces FDA approval of first gene therapy for adults with hemophilia B
- uniQure to Host Virtual Research & Development Event on Tuesday, November 29, 2022
- uniQure Announces Third Quarter 2022 Financial Results and Highlights Recent Company Progress
- uniQure Announces Multiple Presentations at the Upcoming Annual Meeting of The European Society of Gene and Cell Therapy (ESGCT)